UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Respiratory syncytial virus: challenges in diagnosis and impact on the elderly: Recommendations from a multidisciplinary panel

Human vaccines & immunotherapeutics, 2024-12, Vol.20 (1), p.2388943

2024

Volltextzugriff (PDF)

Parental knowledge on the respiratory syncytial virus before the nirsevimab immunization program: Attitudes toward immunization in an autonomous community of Spain

Human vaccines & immunotherapeutics, 2024-12, Vol.20 (1), p.2357439

2024

Volltextzugriff (PDF)

Neutralizing activity of anti-respiratory syncytial virus monoclonal antibody produced in Nicotiana benthamiana

Human vaccines & immunotherapeutics, 2024-12, Vol.20 (1), p.2327142-2327142

2024

Volltextzugriff (PDF)

Immunogenicity, safety and reactogenicity of Ad26.RSV.preF/RSV preF protein vaccine in adults aged 60 to 75 years: A comparison of phase 2b and phase 3 clinical trial material

Human vaccines & immunotherapeutics, 2024-12, Vol.20 (1), p.2383504

2024

Volltextzugriff (PDF)

Implementation of the first respiratory syncytial (RSV) immunization campaign with nirsevimab in an autonomous community in Spain

Human vaccines & immunotherapeutics, 2024-12, Vol.20 (1), p.2365804

2024

Volltextzugriff (PDF)

Exploring parental perspectives: Maternal RSV vaccination versus infant RSV monoclonal antibody

Human vaccines & immunotherapeutics, 2024-12, Vol.20 (1), p.2341505

2024

Volltextzugriff (PDF)

Adjuvant system AS01: from mode of action to effective vaccines

Expert review of vaccines, 2024-12, Vol.23 (1), p.715-729

2024

Volltextzugriff (PDF)

Economic burden of respiratory syncytial virus disease in Latin America: A systematic review

Human vaccines & immunotherapeutics, 2024-12, Vol.20 (1), p.2381298

2024

Volltextzugriff (PDF)

Immunogenicity and safety of Ad26.RSV.preF/RSV preF protein vaccine at predicted intermediate- and end-of-shelf-life as an evaluation of potency throughout shelf life

Human vaccines & immunotherapeutics, 2024-12, Vol.20 (1), p.2344970-2344970

2024

Volltextzugriff (PDF)

A latent class analysis of factors influencing preferences for infant respiratory syncytial virus (RSV) preventives among pregnant people in the United States

Human vaccines & immunotherapeutics, 2024-12, Vol.20 (1), p.2358566-2358566

2024

Volltextzugriff (PDF)

Seasonal influenza vaccine performance and the potential benefits of mRNA vaccines

Human vaccines & immunotherapeutics, 2024-12, Vol.20 (1), p.2336357-2336357

2024

Volltextzugriff (PDF)

Economic burden of cardiorespiratory hospitalizations associated with respiratory syncytial virus among United States adults in 2017-2019

Human vaccines & immunotherapeutics, 2024-12, Vol.20 (1), p.2364493

2024

Volltextzugriff (PDF)

Respiratory syncytial virus immunization patterns in Germany, 2015-2020

Human vaccines & immunotherapeutics, 2024-12, Vol.20 (1), p.2380110

2024

Volltextzugriff (PDF)

Respiratory syncytial virus knowledge, attitudes, and perceptions among adults in the United States

Human vaccines & immunotherapeutics, 2024-12, Vol.20 (1), p.2303796

2024

Volltextzugriff (PDF)

Perceptions about respiratory syncytial virus (RSV) and attitudes toward the RSV vaccine among the general public in China: A cross-sectional survey

Human vaccines & immunotherapeutics, 2024-12, Vol.20 (1), p.2310916-2310916

2024

Volltextzugriff (PDF)

Immunogenicity and safety of different dose levels of Ad26.RSV.preF/RSV preF protein vaccine in adults aged 60 years and older: A randomized, double-blind, placebo-controlled, phase 2a study

Vaccine, 2024-12, Vol.42 (26), p.126273, Article 126273

2024

Volltextzugriff (PDF)

Advances in the understanding of circRNAs that influence viral replication in host cells

Medical microbiology and immunology, 2024-12, Vol.213 (1), p.1, Article 1

2024

Volltextzugriff (PDF)

Vaccines for Respiratory Syncytial Virus Prevention in Older Adults

The Annals of pharmacotherapy, 2024-12, Vol.58 (12), p.1218-1228

2024

Volltextzugriff (PDF)

Antibody levels against respiratory syncytial virus fusion protein conformations and lack of association with life-threatening infection in previously healthy infants

Vaccine, 2024-11, Vol.42 (25), p.126119, Article 126119

2024

Volltextzugriff (PDF)

Vaccination against RSV infections - update and perspective

Deutsche medizinische Wochenschrift (1946), 2024-11, Vol.149 (22), p.1341

2024

Volltextzugriff (PDF)

No More Needles: Gentle nasal sprays are being tested as vaccines against COVID, the flu, RSV, and more. They may work better than shots in the arm

Scientific American, 2024-11, Vol.331 (4), p.34

Sutherland, Stephani

2024

Volltextzugriff (PDF)

Advancement in the development of mRNA‐based vaccines for respiratory viruses

Immunology, 2024-11, Vol.173 (3), p.481-496

2024

Volltextzugriff (PDF)

Vaccinations in pulmonary diseases - part 2: herpes zoste, RSV, pneumococcal infection and pertussis

Deutsche medizinische Wochenschrift (1946), 2024-11, Vol.149 (22), p.1372

2024

Volltextzugriff (PDF)

Cost-effectiveness of vaccinating adults aged 60 years and older against respiratory syncytial virus

Vaccine, 2024-10, Vol.42 (24), p.126294, Article 126294

2024

Volltextzugriff (PDF)

1 – 25 von 7.412

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(6.916)
Mit Volltextzugriff
(5.662)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

15 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(6.451)
Life Sciences & Biomedicine
(6.126)
Humans
(5.162)
Respiratory Syncytial Virus
(4.619)
Immunology
(3.850)
Animals
(2.770)
Female
(2.439)
Infectious Diseases
(2.250)
Infant
(2.166)
Respiratory Syncytial Viruses - Immunology
(2.143)
Respiratory Syncytial Virus Infections - Immunology
(1.992)
Biological And Medical Sciences
(1.944)
Microbiology
(1.834)
Male
(1.719)
Virology
(1.621)
Viruses
(1.601)
Infections
(1.412)
Mice
(1.373)
Child, Preschool
(1.277)
Medical Sciences
(1.276)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

MEDLINE
(6.682)
EZB Free E-Journals
(4.496)
Ingenta
(3.285)
Journals@Ovid Full Text
(3.090)
Publisher or Other Site
(2.298)
IngentaConnect Journals
(1.631)
Elsevier ScienceDirect Journals Complete
(1.439)
Elsevier Journal Backfiles on ScienceDirect (DFG Nationallizenzen)
(1.269)
Oxford University Press Journals Current
(865)
Wiley Online Library - AutoHoldings Journals
(799)
Jstor Complete Legacy
(779)
Oxford Journals 2020 Medicine
(770)
Wiley Online Library Full Collection 2018
(604)
Springer Nature - Complete Springer Journals
(334)
Nature
(248)
Taylor & Francis Journals
(237)
Taylor & Francis
(222)
Taylor & Francis Online
(189)
Nexis Uni
(187)
SpringerLINK Contemporary (Konsortium Baden-Württemberg)
(185)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(61)
... seit 30 Tagen
(14)

Menü

Weitere Dienste

Einstellungen

Respiratory syncytial virus: challenges in diagnosis and impact on the elderly: Recommendations from a multidisciplinary panel

Parental knowledge on the respiratory syncytial virus before the nirsevimab immunization program: Attitudes toward immunization in an autonomous community of Spain

Neutralizing activity of anti-respiratory syncytial virus monoclonal antibody produced in Nicotiana benthamiana

Immunogenicity, safety and reactogenicity of Ad26.RSV.preF/RSV preF protein vaccine in adults aged 60 to 75 years: A comparison of phase 2b and phase 3 clinical trial material

Implementation of the first respiratory syncytial (RSV) immunization campaign with nirsevimab in an autonomous community in Spain

Exploring parental perspectives: Maternal RSV vaccination versus infant RSV monoclonal antibody

Adjuvant system AS01: from mode of action to effective vaccines

Economic burden of respiratory syncytial virus disease in Latin America: A systematic review

Assessment of effectiveness and impact of universal prophylaxis with nirsevimab for prevention of hospitalizations due to respiratory syncytial virus in infants. The NIRSE-GAL study protocol

Immunogenicity and safety of Ad26.RSV.preF/RSV preF protein vaccine at predicted intermediate- and end-of-shelf-life as an evaluation of potency throughout shelf life

A latent class analysis of factors influencing preferences for infant respiratory syncytial virus (RSV) preventives among pregnant people in the United States

Seasonal influenza vaccine performance and the potential benefits of mRNA vaccines

Economic burden of cardiorespiratory hospitalizations associated with respiratory syncytial virus among United States adults in 2017-2019

Respiratory syncytial virus immunization patterns in Germany, 2015-2020

Respiratory syncytial virus knowledge, attitudes, and perceptions among adults in the United States

Perceptions about respiratory syncytial virus (RSV) and attitudes toward the RSV vaccine among the general public in China: A cross-sectional survey

Immunogenicity and safety of different dose levels of Ad26.RSV.preF/RSV preF protein vaccine in adults aged 60 years and older: A randomized, double-blind, placebo-controlled, phase 2a study

Advances in the understanding of circRNAs that influence viral replication in host cells

Vaccines for Respiratory Syncytial Virus Prevention in Older Adults

Antibody levels against respiratory syncytial virus fusion protein conformations and lack of association with life-threatening infection in previously healthy infants

Vaccination against RSV infections - update and perspective

No More Needles: Gentle nasal sprays are being tested as vaccines against COVID, the flu, RSV, and more. They may work better than shots in the arm

Advancement in the development of mRNA‐based vaccines for respiratory viruses

Vaccinations in pulmonary diseases - part 2: herpes zoste, RSV, pneumococcal infection and pertussis

Cost-effectiveness of vaccinating adults aged 60 years and older against respiratory syncytial virus

Suchergebnisse filtern